It has been shown to degrade SMARCA2 and SMARCA4 in various cancer cells, deplete SMARCA2 in SMARCA4-mutant AML, and cause decreased cell proliferation and cell death [154]. This evidence concerns the gene SMARCA2 and acute myeloid leukemia.